Warren Lammert

Founded in 2004, Granite Point Capital Management LP is a hedge fund manager located in Boston, Massachusetts.

Engage Therapeutics, Inc. engages in the development of rescue therapy for uncontrolled epileptic seizures. The company was founded by Gregory T. Mayes III and Jouko Isojarvi in 2017 and is headquartered in Summit, NJ.

Tevard Biosciences, Inc. is a biotechnology company based in Cambridge, MA. Tevard Biosciences is focused on developing trna-based and other modulating therapies to cure a broad range of genetic diseases. The company is advancing the use of its novel suppressor trna, enhancer trna, and mrna amplifier platforms in neurological disorders, heart disease, and muscular dystrophies. The company was founded in 2017 by Warren Burt Lammert, Harvey F. Lodish, Daniel Fischer, and Jeffrey Coller. Daniel Fischer has been the CEO since 2017.

Receptor Life Sciences, Inc. operates as a pharmaceutical development company. It offer treatment of pain, central nervous systems, metabolic disorders, and gastrointestinal disorders. The company was founded in 2015 and is headquartered in Seattle, WA.

Janus Henderson Investors US LLC (JHIUS) is a registered investment advisor and mutual fund manager headquartered in Denver, Colorado. The firm was founded in 1969 and formerly known as Janus Capital Management LLC. They are a subsidiary of Janus Henderson US (Holdings) Inc., which is owned by Janus Henderson Group plc (NYSE: JHG, LON: 0RPW) in Great Britain. JHIUS provides investment management services, as an investment adviser or sub-adviser, to pooled investment vehicles.

Fred Alger Management LLC (FAM) is a SEC-registered investment advisor and mutual fund manager headquartered in New York City. The firm is wholly-owned by Alger Group Holdings LLC, which in turn is wholly-owned by Alger Associates, Inc. Founded in 1964, FAM provides both discretionary and non-discretionary investment advisory services to institutional investors through separate accounts, US and foreign registered and privately offered funds, as well as through a third-party sponsored bank collective investment trust; and to retail investors through wrap programs and US and foreign registered pooled investment vehicles.

Cerebral Therapeutics, Inc. develops neurological therapeutics for uncontrolled neurological diseases. It is a clinical-stage company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. The firm offers long-term implanted drug-device combination therapies that bypass the blood-brain barrier to deliver optimal doses of specially formulated neurological therapeutics directly into the target region of the brain. The company was founded by Daniel J. Abrams and James P. Kelleher and is headquartered in Aurora, CO.

Biscayne Pharmaceuticals, Inc. develops drugs and pharmaceutical products. It offers drugs for CNS disorders such as refractory epilepsy and drug-resistant cancer. The firm also provides cancer therapies that block growth hormone-releasing hormone (GHRH) receptors. The company was founded by Andrew V. Schally and Samuel J. Reich in 2012 and is headquartered in Miami, FL.

Biscayne Neurotherapeutics, Inc. engages in the development of novel treatments for epilepsy, pain and other central nervous system (CNS) disorders. The company was founded by Samuel J. Reich on November 15, 2011 and is headquartered in Miami, FL.